Delivery Order SPE2DB22D9367-SPE2DB25FSZ99
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $42,592.16 for the supply of Iclusig 15 mg tablets (30-count units) by the Defense Logistics Agency on March 12, 2025. This firm fixed-price delivery order, with an ultimate completion date of April 2, 2025, carries no set-aside designation. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $42,891.80 by the Defense Logistics Agency on August 7, 2025, for the supply of ICLUSIG 45 mg tablets (30-count units). The contract, which carries no set-aside designation, is scheduled for completion by August 28, 2025, and represents a targeted pharmaceutical delivery to support federal healthcare operations. This award is...
- The Defense Logistics Agency awarded a delivery order valued at $21,651.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of ICLUSIG 30 mg tablets (30-count). The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 22, 2025, and was awarded on August 29, 2025. This award does not utilize a set-aside designation, allowing the vendor to compete on an open...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $171,788.80 on August 20, 2025, for the supply of Iclusig 30 mg tablets (30-count packages). The contract, with an ultimate completion date of September 11, 2025, is funded through the Defense Logistics Agency's Medical Supply Chain program and carries no set-aside designation. This delivery order is issued under DMS...
- On April 24, 2025, the Defense Logistics Agency (DLA), operating under the Department of Defense's Medical Supply Chain, awarded a delivery order to DMS Pharmaceutical Group Inc. for the supply of ICLUSIG 15 mg tablets (30-count units) with a ceiling value of $42,592.16. This firm fixed-price delivery order, expected to be completed by May 15, 2025, represents a discrete issuance under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at approximately $500 million...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $43.3K for ICLUSIG 30 mg tablets (30-count units) from the Medical Supply Chain, a defense-focused federal agency. This award, issued on August 4, 2025, with an ultimate completion date of August 25, 2025, is a firm fixed-price delivery order with no set-aside designation. The contract represents a single award under DMS Pharmaceutical...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $41,870.16 contract is for the supply of the drug Iclusig 15 mg tablet in 30-count packages, with a completion date of November 19, 2024. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $42,592.16 by the Defense Logistics Agency (DLA) on July 14, 2025, with an ultimate completion date of August 4, 2025. The delivery order, contract number 4568823267, covers the supply of Iclusig 15 mg tablets (30-count units), a specialty oncology medication. This award was issued without a set-aside designation,...
- DMS Pharmaceutical Group Inc. has been awarded a firm fixed price delivery order valued at fifty-eight thousand six hundred ninety-five dollars and forty-two cents ($58,695.42) by the Defense Logistics Agency to supply Iclusig 45 mg tablets. The order was awarded on December 5, 2023 and is to be completed by December 27, 2023. No set-aside designation was applied to this procurement. DMS Pharmaceutical Group is a woman-owned small business and woman-owned business located in Park Ridge, Illinois...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $41,870.16 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of ICLUSIG 15 MG TABLET 30S, a pharmaceutical product, with a period of performance through April 10, 2024. This delivery order is issued under DMS Pharmaceutical Group's larger indefinite delivery vehicle (IDV) contract 4600082013 with DLA, valued at up to...
- SPE2DB22D9367Indefinite Delivery Contract
- SPE2DB22D9367-SPE2DB25FSZ99Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $55,179.60 to DMS Pharmaceutical Group Inc. for the supply of Iclusig 15 mg tablets (30-count units) on September 22, 2025. The award is structured as a firm fixed-price delivery order with an ultimate completion date of October 14, 2025, and represents no specific set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its Park Ridge facility. This award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products supporting military healthcare facilities worldwide. Iclusig (ponatinib) is a targeted oncology therapy used in the treatment of certain blood cancers, and this delivery order ensures the availability of this critical pharmaceutical product within the Defense Logistics Agency's supply chain for Department of Defense healthcare sites. DMS Pharmaceutical Group has established itself as a significant supplier within the federal pharmaceutical distribution network, consistently securing contracts to deliver branded and generic prescription drugs, biologics, and specialized medical supplies to military health facilities across the country. The firm fixed-price structure and expedited completion timeline reflect the essential nature of pharmaceutical supply for defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $55.2k | 9/22/25 |